Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Tetanus × sargramostim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia 40 Melanoma 39 Lymphoma 38 Breast Neoplasms 32 Lymphoma, Follicular 27 Leukemia, Myeloid, Acute 24 Lymphoma, Non-Hodgkin 23 Neuroblastoma 22 Multiple Myeloma 22 Precursor Cell Lymphoblastic Leukemia-Lymphoma 21 Leukemia, Lymphocytic, Chronic, B-Cell 21 Lymphoma, Large B-Cell, Diffuse 19 Prostatic Neoplasms 17 Lymphoma, Mantle-Cell 17 Lymphoma, Large-Cell, Immunoblastic 17 Ovarian Neoplasms 16 Carcinoma, Non-Small-Cell Lung 16 Myelodysplastic Syndromes 15 Lung Neoplasms 15 Glioblastoma 15 Neoplasms, Plasma Cell 14 Neoplasm Metastasis 14 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14 Burkitt Lymphoma 14 Leukemia, Myeloid, Chronic-Phase 13 Hodgkin Disease 12 Gliosarcoma 12 Neoplasms 11 Lymphoma, B-Cell, Marginal Zone 11 Carcinoma, Ovarian Epithelial 11

Interventions

sargramostim 1 Vaccines 1 Temozolomide 1 Papillomavirus Vaccines 1 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03927222 2024-04-08

I-ATTAC

Duke University

Phase 2 Terminated

6 enrolled 7 charts

Glioblastoma, Tetanus

Data powered by HemOnc (CC BY 4.0) Colophon ⚡